37 results on '"Zhu, D."'
Search Results
2. 1036P Anlotinib plus docetaxel vs. docetaxel as 2nd-line treatment of advanced non-small cell lung cancer (NSCLC): Updated results from ALTER-L016
3. 14P Circulating tumor DNA (ctDNA) residual and dynamics of ctDNA clonality indicated therapeutic efficacy of sintilimab plus docetaxel in previously treated advanced non-small cell lung cancer
4. 1334P Efficacy and safety of anlotinib plus docetaxel in non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Results from a phase I/II trial
5. 1266P Genetic profiling of cell-free DNA from pleural effusion in advanced lung cancer as a surrogate for tumor tissue and revealed additional clinical actionable targets
6. 1335P Updated results from a phase I/II study of anlotinib plus docetaxel vs docetaxel as second-line treatment of advanced non-small cell lung cancer (NSCLC)
7. LBA79 GEMSTONE-303: Prespecified progression-free survival (PFS) and overall survival (OS) final analyses of a phase III study of sugemalimab plus chemotherapy vs placebo plus chemotherapy in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
8. 1060P Balance of CD36+ and CD16+ monocytes controls TLR-mediated cytokine release syndrome and MHC-dependent antitumor responses in EpCAM CAR T cell therapy for gastrointestinal cancers
9. 1049P Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors
10. 623P VIC regimen (vemurafenib/irinotecan/cetuximab) versus bevacizumab plus chemotherapy as first-line treatment for BRAF V600E-mutated advanced colorectal cancer
11. GDF15 is a potential predictive biomarker for TPF induction chemotherapy and promotes tumorigenesis and progression in oral squamous cell carcinoma
12. 402P Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
13. 1360P Identification of epidermal growth factor receptor (EGFR) fusions in a large Chinese lung cancer population
14. TUMOR RESPONSE AND SECONDARY RESECTABILITY OF COLORECTAL LIVER METASTASES FOLLOWING CETUXIMAB WITH CHEMOTHERAPY: A RANDOMIZED, CONTROLLED STUDY
15. Robot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer
16. Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial
17. Inhibitory effect of recombinant adenovirus carrying melittin gene on hepatocellular carcinoma
18. 1123P Real-world outcomes of first-line osimertinib for EGFR mutated advanced NSCLC patients in China: Interim analysis of the FLOURISH study
19. 86P Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study.
20. Robot-assisted vs laparoscopic vs open abdominoperineal resections for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial
21. LBA31 - Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial
22. 558P - Robot-assisted natural orifice specimen extraction surgery for radical resection of colorectal cancer
23. 176P Robotic anterior resection of rectal cancer without abdominal incision: transanal rectal eversion and resection for specimen extraction: A preliminary and feasibility study
24. Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese trial
25. 482PD - Robot-assisted vs laparoscopic vs open abdominoperineal resections for low rectal cancer: Short-term outcomes of a single-center prospective randomized controlled trial
26. 541P - Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese trial
27. Early Tumor Shrinkage as Predictor of Outcome in Colorectal Liver Metastases Treated with Cetuximab Plus Chemotherapy
28. Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
29. BRAF, PIK3CA Alterations can Predict Outcomes to Cetuximab Contained Conversion Chemotherapy in Wild-Type KRAS CLM
30. Survival Investigation in Patients with Colorectal Liver Metastasis: A Single-Institution Analysis
31. Outcome of Patients with Colorectal Liver Metastasis: Analysis of 1613 Consecutive Cases
32. Survival Analysis of 1,061 Patients with Synchronous Colorectal Hepatic Metastases
33. The Predictive Role of MTHFR and ABCG2 Single Nucleotide Polymorphisms on the Outcome of Advanced Colorectal Cancer Treated with First-Line Chemotherapy
34. O2–092EFFECT OF NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH RESECTABLE COLORECTAL LIVER METASTASES.
35. 563P Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study).
36. IS3–3EARLY TUMOR SHRINKAGE AS PREDICTOR OF OUTCOME IN COLORECTAL LIVER METASTASES TREATED WITH CETUXIMAB PLUS CHEMOTHERAPY.
37. O2–081BRAF, PIK3CA ALTERATIONS CAN PREDICT OUTCOMES TO CETUXIMAB CONTAINED CONVERSION CHEMOTHERAPY IN WILD-TYPE KRAS CLM.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.